Patents by Inventor Jeffrey B. Smaill

Jeffrey B. Smaill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimido[5,4-d]pyrimidines derivatives as irreversible inhibitors of tyrosine kinases
    Patent number: 7786131
    Abstract: The present invention relates to pyrimido [5,4-d] pyrimidine compounds of Formula II or a pharmaceutically acceptable salt thereof, wherein Q is and X, E1, E2, E3, R6 and p are as defined herein. The compounds of this invention are irreversible inhibitors of tyrosine kinases and are useful in the treatment of cancer, atherosclerosis, restenosis, endometriosis and psoriasis.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: August 31, 2010
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
  • Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
    Publication number: 20100173332
    Abstract: A method utilising one or more fluorogenic probes, for the detection of nitroreductase activity. The non-fluorescent probes are reduced in the presence of nitroreductase to form fluorescent derivatives that may be detected using fluorescence spectroscopy.
    Type: Application
    Filed: September 7, 2007
    Publication date: July 8, 2010
    Inventors: Jeffrey B. Smaill, Adam V. Patterson, Dean C. Singleton
  • Irreversible inhibitors of tyrosine kinases
    Publication number: 20030229051
    Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
    Type: Application
    Filed: May 20, 2003
    Publication date: December 11, 2003
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalker, Jeffrey B. Smaill, Hairong Zhou
  • Irreversible inhibitors of tyrosine kinases
    Patent number: 6602863
    Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: August 5, 2003
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
  • Irreversible inhibitors of tyrosine kinases
    Patent number: 6344459
    Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 5, 2002
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
  • DNA-targeted alkylating agents
    Patent number: 5968933
    Abstract: The invention relates to novel bis-benzimidazole compounds which have the ability to bind to the minor groove of DNA and to alkylate DNA, to methods of preparing the compounds, and the use of the compounds in the treatement of neoplastic disease.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: October 19, 1999
    Assignees: Auckland Division Cancer Society of New Zealand Inc., Circadian Pharmaceuticals (Australia) Pty. Ltd.
    Inventors: William A. Denny, Jeffrey B. Smaill